Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

554 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes.
Martin ES, Ferrer A, Mangaonkar AA, Khan SP, Kohorst MA, Joshi AY, Hogan WJ, Olteanu H, Moyer AM, Al-Kali A, Tefferi A, Chen D, Wudhikarn K, Go R, Viswanatha D, He R, Ketterling R, Nguyen PL, Oliveira JL, Gangat N, Lasho T, Patnaik MM. Martin ES, et al. Among authors: hogan wj. Am J Hematol. 2021 Nov 1;96(11):1450-1460. doi: 10.1002/ajh.26321. Epub 2021 Aug 27. Am J Hematol. 2021. PMID: 34390506 Free article.
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM. Tefferi A, et al. Among authors: hogan wj. Blood. 2006 Aug 15;108(4):1158-64. doi: 10.1182/blood-2006-02-004572. Epub 2006 Apr 11. Blood. 2006. PMID: 16609064 Free article. Clinical Trial.
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.
Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A. Pardanani AD, et al. Among authors: hogan wj. Blood. 2006 Nov 15;108(10):3472-6. doi: 10.1182/blood-2006-04-018879. Epub 2006 Jul 25. Blood. 2006. PMID: 16868251 Free article.
JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival.
Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ, Elliott MA, Litzow MR, Hanson CA, Pardanani A. Tefferi A, et al. Among authors: hogan wj. Leukemia. 2010 Jan;24(1):105-9. doi: 10.1038/leu.2009.225. Epub 2009 Oct 22. Leukemia. 2010. PMID: 19847199
Phase1/-2 study of Pomalidomide in myelofibrosis.
Mesa RA, Pardanani AD, Hussein K, Wu W, Schwager S, Litzow MR, Hogan WJ, Tefferi A. Mesa RA, et al. Among authors: hogan wj. Am J Hematol. 2010 Feb;85(2):129-30. doi: 10.1002/ajh.21598. Am J Hematol. 2010. PMID: 20052748 Free article. Clinical Trial. No abstract available.
554 results